Skip to content

Cardiac Resynchronization Therapy Modular Registry

Cardiac Resynchronization Therapy Modular Registry

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01573091
Acronym
CRT-MORE
Enrollment
500
Registered
2012-04-06
Start date
2011-12-31
Completion date
2015-12-31
Last updated
2017-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Cardiac resynchronization therapy, Heart failure

Brief summary

The purpose of the study is to collect some parameters (clinical, electrical, radiographic, echocardiographic and ECG) able to predict response to cardiac resynchronization therapy.

Detailed description

Heart failure is a complex clinical syndrome characterized by a high prevalence and incidence in populations at greatest risk and, therefore, with a significant social and economic impact. Randomized clinical trials, meta-analyzes, observational studies and controlled trials clearly demonstrated that the neuro-hormonal therapy is highly effective in reducing mortality, hospitalization and improving quality of life. In recent years the electrical therapy is playing an increasingly important role in the treatment of patients with chronic heart failure. Such importance is mainly due to the possibility of preventing sudden cardiac death by implanting an ICD and to correct the deleterious effects of electrical dyssynchrony and / or left ventricular mechanics by CRT. The CRT has proven an effective tool in reducing mortality, reducing symptoms and improving quality of life in patients already receiving optimal medical therapy. Despite the undoubted benefits that the electrical treatment has added to conventional medical therapy, a high percentage of patients does not benefit in terms of clinical and echocardiographic. The identification of non-responders to CRT is crucial in order not to submit the patients to an unnecessary and costly device whose electrical therapy proves to be ineffective. The reason for lack of response is still unclear but factors such as lead placement, device-settings and the degree of dyssynchrony before implant seems to be important. The purpose of the study is to collect some parameters (clinical, electrical, radiographic, echocardiographic and ECG) able to predict response to cardiac resynchronization therapy.

Interventions

PROCEDURECardiac Resynchronization Therapy

Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines

Sponsors

Giuseppe Ricciardi
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic symptomatic HF despite stable, optimal drug therapy * Indication for a cardiac resynchronisation device with or without defibrillator backup according to current guidelines * Patients implanted with cardiac resynchronization device

Exclusion criteria

* Patients participating in other studies that clearly impact the clinical practice of the center * Patients who are unable to provide informed consent * Patients who can not perform follow-up in the center

Design outcomes

Primary

MeasureTime frameDescription
Clinical response24 monthsImprovement in functional class status by at least one NYHA Class or remain in functional class II
Echocardiographic response of absolute increase of ≥5% in LVEF24 monthsPatients at follow-up to 6-12 months show an increase of the absolute value of the LVEF than 5%
Echocardiographic response of ≥15% reduction in LVESV24 monthsPatients at follow-up to 6-12 months show a systolic volume (LVESV) reduction greater than 15%

Secondary

MeasureTime frameDescription
LV lead/RV lead geometric distance12 monthsTo investigate the correlation of LV lead/RV lead geometric distance (as measured by fluoroscopy) and reverse remodeling in cardiac resynchronization therapy (as measured by echocardiography as defined in primary outcome measure) at 12 months. The relation with LVESVi change between baseline and 12 months will be analyzed.
Change from baseline in R wave in 12-lead ECG at 12 months12 monthsTo investigate the relationship between the ECG characteristics at baseline and response to cardiac resynchronization therapy (as measured by echocardiography as defined in primary outcome measure) at 12 months. The purpose of this objective is to evaluate the R wave in 12-lead ECG during BIV, RV and LV pacing and change from baseline at 12 months.
Number of ventricular arrhythmias after cardiac resynchronization therapy24 monthsTo investigate the relationship between LV pacing and the number of ventricular tachycardia/fibrillation and/or appropriate/inappropriate shocks. The number and type of arrhythmia before and after upgrading to CRT device at 24 months will be analyzed

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026